Vnitr Lek 2025, 71(4):218-223 | DOI: 10.36290/vnl.2025.040

Current biological therapies for bronchial asthma

Martina Kulířová, Vratislav Sedlák
Plicní klinika Fakultní nemocnice Hradec Králové, Univerzita Karlova v Praze, Lékařská fakulta v Hradci Králové

The prevalence of bronchial asthma is increasing and severe asthma, which is not controlled even with optimal therapy with a high dose of inhaled corticosteroid in combination with a long-acting β2-mimetic, affects up to 10 % of asthmatics. Severe asthma is associated with a higher risk of fixed bronchial obstruction, acute exacerbations, impaired quality of life and financial burden on the healthcare system. Biological treatment of asthma should be considered in all patients who, despite optimal treatment of asthma and its comorbidities, experience acute exacerbations or use chronic systemic corticotherapy due to asthma. Currently, we have five agents available in the Czech Republic to treat patients with severe asthma. These biologics are directed against cytokines involved in the pathogenesis of eosinophilic inflammation (interleukin 4, 5 and 13), against immunoglobulin E or against thymic stromal lymphopoietin. This review article briefly and clearly discusses the basics of current options and indications for biologic treatment of severe bronchial asthma.

Keywords: severe asthma, biological therapy, monoclonal antibodies.

Accepted: June 3, 2025; Published: June 19, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kulířová M, Sedlák V. Current biological therapies for bronchial asthma. Vnitr Lek. 2025;71(4):218-223. doi: 10.36290/vnl.2025.040.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Global Initiative for Asthma. 2024 GINA report, global strategy for asthma management and prevention (2024 update) (https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf)
    2. Global Initiative for Asthma. Difficult-to-treat and severe asthma in adolescent and adult patients: doagnosis and management. A GINA pocket guide for health professionals. April 2021 (https://ginasthma.org/wp-content/uploads/2021/08/SA-Pocket-guide-v3.0-SCREEN-WMS.pdf).
    3. Settipane RA, Kreindler JL, Chung Y, Tkacz J. Evaluating direct costs and productivity losses of patients with asthma recieving GINA 4/5 therapy in the United States. Ann Allergy Asthma Immunol 2019;123(6):564-572.e.3. Go to original source... Go to PubMed...
    4. Cisternas MG, Blanc PD, Yen IH, et al. A comprehensive study of the direct and indirect costs of adult asthma. J Allergy Clin Immunol 2003;111:1212-1218. Go to original source... Go to PubMed...
    5. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014 Feb;43(2):343-73. Go to original source... Go to PubMed...
    6. Skov I.R., Madsen H., Henriksen D.P., Andersen J.H., Pottegård A., Davidsen J.R. Low dose oral corticosteroids in asthma associates with increased morbidity and mortality. Eur Respir J. 2022;60(3) Go to original source... Go to PubMed...
    7. Heatley H., Tran T.N., Bourdin A., et al. Observational UK cohort study to describe intermittent oral corticosteroid prescribing patterns and their association with adverse outcomes in asthma. Thorax. 2023;78(9):860-867. Go to original source... Go to PubMed...
    8. Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med. 2022 Jan 13;386(2):157-171. Go to original source... Go to PubMed...
    9. Hanania N.A., Wenzel S., Roseń K., et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med. 2013;187(8):804-811. Go to original source... Go to PubMed...
    10. Casale T.B., Luskin A.T., Busse W., et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7(1):156-164.e1. Go to original source... Go to PubMed...
    11. Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol 2003;111:714-719. Go to original source... Go to PubMed...
    12. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 2014;371:1198-1207. Go to original source... Go to PubMed...
    13. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380(9842):651-9. Go to original source... Go to PubMed...
    14. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3 b trial. Lancet Respir Med 2017;5:390-400. Go to original source... Go to PubMed...
    15. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189-97. Go to original source... Go to PubMed...
    16. Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, Valero A, Gemzoe K, Maxwell A, Joksaite S, Yang S, Howarth P, Van Dyke MK. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151. Go to original source... Go to PubMed...
    17. Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2115-2127. Go to original source... Go to PubMed...
    18. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016 Oct 29;388(10056):2128-2141. Go to original source... Go to PubMed...
    19. Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448-2458. Go to original source... Go to PubMed...
    20. Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496. Go to original source... Go to PubMed...
    21. Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475-2485. Go to original source... Go to PubMed...
    22. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021. Go to original source... Go to PubMed...
    23. Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022;10(7):650-660. Go to original source... Go to PubMed...
    24. Couillard S, Jackson DJ, Pavord ID, Wechsler ME. Choosing the Right Biologic for the Right Patient With Severe Asthma. Chest. 2025 Feb;167(2):330-342. Go to original source... Go to PubMed...
    25. Kelsen SG, Agache IO, Soong W, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J Allergy Clin Immunol. 2021 Sep;148(3):790-798. Go to original source... Go to PubMed...
    26. Wechsler ME, Ruddy MK, Pavord ID, et. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N Engl J Med. 2021 Oct 28;385(18):1656-1668. Go to original source... Go to PubMed...
    27. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024 Dec 19;391(24):2337-2349. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.